Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of MenACWY-TT formulations versus Mencevax ACWY in healthy adolescents and young adults
2005-000965-21Phase 2Completed
- Sponsor
- GSK
- Start
- Apr 2005
- Modality
- Vaccines & Immunotherapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of meningococcal group A, C, W, and Y tetanus toxoid conjugate vaccine and meningococcal ACYW135 vaccine in meningococcal disease (5 arms), sponsored by GSK. Primary endpoints: Immune response one month after vaccination and Safety and reactogenicity. Started Apr 2005; status: completed.
02
Drugs
meningococcal group A, C, W, and Y tetanus toxoid conjugate vaccinemeningococcal ACYW135 vaccine
03
Conditions
meningococcal disease
Beyond the preview
Go deeper on 2005-000965-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-000965-21.